Brevital Sodium

(Methohexital)

PreclinicalSmall molecule

AAultman Health Foundation

Brevital Sodium is one of 7 small molecule programs targeting Ketamine. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

KetamineCompleted

KetaminePreclinical

Completed

Competition

Competitive Landscape

9 competitors in Ketamine

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

78 2

Ketalar

Boehringer Ingelheim

Phase 3

10 3

Spravato

WWim Janssens

Phase 2

2 4

Naltrexone Pill

YYale University

Phase 2

1 5

Fycompa

CCatalyst Biosciences

Phase 1

3 6

Ketamin

MMassachusetts General Hospital

Phase 1

1 7

Brevital Sodium

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anesthesia3 trials

Comparison of Esketamine/Propofol and Methohexital Anesthesia for ECT

Recruiting·MMedical University of Vienna·Phase 4·NCT05655754·100 enrolled

Ketamine Anesthesia for Improvement of Depression in ECT

Completed·VVA Puget Sound Health Care System·N/A·NCT02752724·52 enrolled

Ketamine Anesthesia in Electroconvulsive Therapy

Completed·MMayo Clinic·N/A·NCT01367119·38 enrolled

Depression2 trials

Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression

Completed·NNorthwell Health·Phase 4·NCT01881763·31 enrolled

Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression

Terminated·JJames Murrough·N/A·NCT01309581·3 enrolled

Ketamine1 trial

Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time

Completed·UUniversity of New Mexico·N/A·NCT01567852·20 enrolled

Cardioversion1 trial

Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion

Completed·WWake Forest University Health Sciences·Phase 4·NCT04187196·73 enrolled

General Anesthetic1 trial

Methohexital v Propofol as General Anesthetic in Patients on ACEIs or ARBs

Completed·MMilton S. Hershey Medical Center·N/A·NCT02624050·51 enrolled

1 more indication

Tics1 trial

EEG Characteristics in ECT

Completed·UUniversity of New Mexico·Phase 1·NCT04022226·11 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

BREVITAL SODIUM

NDA NDA011559

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Methohexital. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methohexital compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methohexital. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA011559). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Aultman Health Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAultman Health Foundation

Brevital Sodium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anesthesia3 trials

Depression2 trials

Ketamine1 trial

Cardioversion1 trial

General Anesthetic1 trial

Tics1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News